Evidence map›Paper›PMID 39697698›Full record

ArticleTranslational cancer research2024

Construction and validation of a novel prognostic model with palmitoylation-related genes for glioblastoma.

Guowen Qin, Gang Pang, Shuaishuai Wu, Shuiqing Bi, Shengyong Lan, Xiuwen Tang, Beiquan Hu, Junlin Zhou, Fengning Shi, Chengjian Qin

Abstract read
In one paragraph

Article in Translational cancer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Guowen QinDepartment of Neurosurgery, The First Affiliated Hospital of Jinan University, Guangzhou, China.
Gang PangDepartment of Cerebrovascular Disease and Spine Neurosurgery, The People's Hospital of Guangxi Zhuang Autonomous Region, Guangxi Academy of Medical Sciences, Nanning, China.
Shuaishuai WuDepartment of Neurosurgery, The First Affiliated Hospital of Jinan University, Guangzhou, China.
Shuiqing BiDepartment of Cerebrovascular Disease and Spine Neurosurgery, The People's Hospital of Guangxi Zhuang Autonomous Region, Guangxi Academy of Medical Sciences, Nanning, China.
Shengyong LanDepartment of Intracranial Tumor, Cerebral Trauma and Functional Neurosurgery, The People's Hospital of Guangxi Zhuang Autonomous Region, Guangxi Academy of Medical Sciences, Nanning, China.
Xiuwen TangDepartment of Intracranial Tumor, Cerebral Trauma and Functional Neurosurgery, The People's Hospital of Guangxi Zhuang Autonomous Region, Guangxi Academy of Medical Sciences, Nanning, China.
Beiquan HuDepartment of Intracranial Tumor, Cerebral Trauma and Functional Neurosurgery, The People's Hospital of Guangxi Zhuang Autonomous Region, Guangxi Academy of Medical Sciences, Nanning, China.
Junlin ZhouDepartment of Cerebrovascular Disease and Spine Neurosurgery, The People's Hospital of Guangxi Zhuang Autonomous Region, Guangxi Academy of Medical Sciences, Nanning, China.
Fengning ShiDepartment of Intracranial Tumor, Cerebral Trauma and Functional Neurosurgery, The People's Hospital of Guangxi Zhuang Autonomous Region, Guangxi Academy of Medical Sciences, Nanning, China.
Chengjian QinDepartment of Neurosurgery, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Glioblastoma multiforme (GBM), the most prevalent and aggressive primary brain tumor, poses substantial challenges in both treatment and prognosis. Post-translational modifications, like palmitoylation, are known to have critical roles in the development and progression of glioma. Yet, the molecular mechanisms involved in palmitoylation and its prognostic significance in GBM are still not fully understood. This study aimed to explore prognostic biomarkers for GBM based on palmitoylation-related genes and to construct a prognostic risk model. Methods: The messenger ribonucleic acid (mRNA) expressions data and the clinical information were downloaded from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) to explore palmitoylation-related mechanisms in GBM. The Cox regression analysis was performed to identify prognostic palmitoylation-related genes and the consensus clustering was used for molecular classification. The package "limma" was used for differential gene expression analysis and the least absolute shrinkage and selection operator (LASSO) regression was applied to construct a risk signature. A nomogram model was established using the risk score and clinical variables. Receiver operating characteristic (ROC), calibration curve, and decision curve analysis (DCA) were used to assess the predicted accuracy and clinical benefit of the model. The difference in immune cell infiltration was compared between different risk groups. The drug susceptibility analysis and immunotherapy response prediction were conducted to access the ability of the risk signature in predicting the therapeutic effect. Results: Based on datasets from TCGA, five palmitoylation-related genes were identified as prognostic markers, allowing for the categorization of GBM patients into two subtypes with differing survival rates. Through differential expression analysis, 570 specific genes linked to GBM advancement were uncovered. A total of seven signature genes ( Conclusions: Our study offers insights into the molecular classification and prognostic assessment of GBM, focusing on palmitoylation-related mechanisms. The prognostic model we constructed provides valuable guidance for tailoring personalized treatment strategies for GBM patients.

Indexed as

Glioblastoma multiforme (GBM)immune infiltrationpalmitoylationprognostic model

Identifiers

PMID39697698
PMCPMC11651772

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.